Informations générales (source: ClinicalTrials.gov)
Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis
Interventional
Phase 4
Erasmus Medical Center (Voir sur ClinicalTrials)
janvier 2025
décembre 2027
07 août 2026
The aim of this study is to investigate if an initial short double dose of beta-lactam
antibiotics will reduce mortality in critically ill patients with sepsis.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Sandrine GARDE | 07/08/2026 13:35:04 | Contact (sur clinicalTrials) | ||
Critères
Tous
- ≥18 years of age
- Receiving intravenous antibiotic therapy of the target drugs (including continuous
infusion of beta-lactam antibiotics)
- Primary infection
- Admitted to the ICU
- Meeting the Sepsis-3 criteria for septic shock: sepsis in addition to shock
requiring the start of vasopressors to maintain a mean arterial pressure 65 mmHg or
greater, and a serum lac tate level greater than 2.0 mmol/L following "adequate
fluid resuscitation".
Exclusion Criteria:
- Patient or legal representative not available to give informed consent within 72
hours after admittance
- Pregnancy
- Admittance for burn wounds
- Patients receiving target antibiotics only as prophylaxis within the context of
Selective Diges tive tract Decontamination (SDD)
- Enrolment in another interventional trial
- Patient received the study antibiotic for more than 24 hours before inclusion
- Patient receiving extracorporeal membrane oxygenation (ECMO)
- Patient is already treated with a double dose of antibiotics based on suspected
infection